10/12/2026
OS Therapies’ work in comparative oncology is rooted in the development history of OST-HER2.
Canine osteosarcoma research helped catalyze the human clinical development of the Listeria-based immunotherapy platform. That early connection continues today through two separate programs focused on naturally occurring osteosarcoma.
OS Therapies is advancing OST-HER2 in human osteosarcoma, while its subsidiary, OS Animal Health, is focused on advancing the therapy for canine osteosarcoma.
Learn more about the company's work: https://ostherapies.com/